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Crystal Structure of the FHA Domain
of the Chfr Mitotic Checkpoint Protein
and Its Complex with Tungstate
respectively, and show overall similar folds for the two
FHA domains. However, there are differences in the in-
teractions with the phosphopeptides, and several highly
conserved FHA domain residues are not involved in
phosphopeptide binding in either structure [4–7].
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Wistar Institute We recently reported the cloning of chfr, a mitotic
checkpoint gene that functions in early mitosis to delayPhiladelphia, Pennsylvania 19104
2 Cell and Molecular Biology Program progression through prophase in response to mitotic
stress [8]. chfr is frequently inactivated in human cancer3 Biochemistry and Biophysics Program
Biomedical Graduate Studies cell lines, and its inactivation confers sensitivity to mi-
crotubule poisons, such as taxol, which is being used for4 Department of Pathology and Laboratory Medicine
University of Pennsylvania cancer therapy. The protein encoded by chfr contains an
FHA domain at its N terminus. By analogy to Rad53,Philadelphia, Pennsylvania 19104
5 Cellular Biochemistry and Biophysics Program whose two FHA domains have been shown to bind phos-
phopeptides, Chfr may utilize its FHA domain to bind6 Howard Hughes Medical Institute
Memorial Sloan-Kettering Cancer Center to phosphorylated proteins. However, neither physio-
logical substrates of Chfr nor peptides that can bind toNew York, New York 10021
its FHA domain in vitro are known. To better understand
the function of the FHA domain of Chfr and to explore
its ability to recognize phosphoproteins, we determinedSummary
its three-dimensional structure in its native form and in
complex with tungstate, an analog of phosphate. TheThe Chfr mitotic checkpoint protein is frequently inac-
tivated in human cancer. We determined the three- structures revealed a  sandwich fold similar to the pre-
viously determined folds of the Rad53 N- and C-terminaldimensional structure of its FHA domain in its native
form and in complex with tungstate, an analog of phos- FHA domains. However, the Rad53 domains were mono-
meric, whereas the Chfr FHA domain crystallized as aphate. The structures revealed a  sandwich fold simi-
lar to the previously determined folds of the Rad53 N- segment-swapped dimer. The tungstate ion was bound
by a cluster of conserved FHA domain residues; this isand C-terminal FHA domains, except that the Rad53
domains were monomeric, whereas the Chfr FHA do- similar to the way that phosphate is recognized by the
Rad53 N-terminal FHA domain but unlike phosphatemain crystallized as a segment-swapped dimer. The
ability of the Chfr FHA domain to recognize tungstate recognition by the Rad53 C-terminal FHA domain. Thus,
the Chfr FHA domain shares the ability with other FHAsuggests that it shares the ability with other FHA do-
mains to bind phosphoproteins. Nevertheless, differ- domains to bind phosphoproteins, although differences
in the mechanism of tungstate/phosphate binding sug-ences in the sequence and structure of the Chfr and
Rad53 FHA domains suggest that FHA domains can be gest that FHA domains can be divided into families with
distinct binding properties.divided into families with distinct binding properties.
Introduction Results and Discussion
Overall StructureThe forkhead-associated (FHA) domain was originally
described as a small domain in transcription factors with Several fragments of Chfr containing the FHA domain
were expressed in E. coli and characterized for solubilityforkhead-type DNA binding domains [1]. More recently,
FHA domains have also been identified in protein ki- and resistance to proteolysis in the presence of subtil-
isin. The smallest soluble and proteolysis-resistant poly-nases and other proteins that are not transcription fac-
tors such that most of the proteins now known to contain peptides identified by this analysis consisted of an
N-terminal methionine and residues 14–124 or 14–128FHA domains function in cell cycle control [2]. Biochemi-
cal and structural studies suggest that FHA domains of Chfr. Both polypeptides eluted as single peaks on gel
filtration chromatography, consistent with a monomerare protein-protein interaction domains with specificity
for phosphorylated targets [3–7]. The structural studies form. A selenomethionine derivative of the polypeptide
containing residues 14–128 formed crystals with P3(2)21have focused on the two FHA domains present within
Rad53, a budding yeast DNA damage checkpoint ki- symmetry that diffracted to 2.7 A˚ resolution and had
one molecule in the asymmetric unit. The structure ofnase. Three-dimensional structures of the N-terminal
FHA domain (N-FHA) bound to a phosphothreonine- this polypeptide was determined using anomalous scat-
tering from the selenium and the isomorphous differencecontaining peptide and of the C-terminal FHA domain
(C-FHA) bound to a phosphotyrosine-containing pep- from a selenomethionyl crystal soaked in mercury (Table
1). The polypeptide containing residues 14–124 formedtide have been determined by crystallography and NMR,




Table 1. Data Collection and Refinement Statistics
Molecule Chfr Chfr Chfr-Tungstate
Data Collection
Space group P3(2)21 P2(1)2(1)2(1) P3(2)21
SeMet MAD
Inflection Peak Remote Se/Hg
Wavelength (A˚) 0.979 0.979 0.964 0.979 0.909 1.5418
Resolution (A˚) 2.7 2.7 2.7 3.1 2.0 2.0
Observations 17,346 17,281 17,359 10,888 71,014 37,545
Unique reflections 3,642 3,622 3,643 2,302 13,548 8,015
Data coverage (%) 97.2 97.1 96.9 99.5 96.7 99.5
Rsym 5.3 4.8 4.6 6.7 5.1 6.7
Phasing Statistics
Resolution (A˚) — 18–4.0 18–4.0 20–3.1
Phasing power (centric) — 0.46 0.68 1.52
Phasing power (acentric) — 0.78 1.22 1.95
Rcullis (centric) — 0.87 0.79 0.59
Rcullis (acentric) — 0.90 0.78 0.64
Rcullis (anomalous) — 0.62 0.73 —
Refinement Statistics
Resolution range (A˚) 18–2.7 18–2.1 18–2.0
Reflections used 3,448 11,878 6,719
Protein atoms 904 1,790 904
Water molecules 25 144 63
R factor 0.247 0.242 0.232
Rfree 0.294 0.288 0.289
Rms deviations
Bonds (A˚) 0.008 0.006 0.006
Angles () 1.534 1.298 1.463
Ramachandran plot
Most favored regions (%) 81.4 90.1 84.5
Allowed (%) 18.6 9.9 15.5
Rsym  hi|Ih,i  Ih|hiIh,i for the intensity (I) of i observations of reflection h.
Phasing power  Fi/E, where Fi is the root-mean-square heavy atom structure factor and E is the residual lack of closure error.
Rcullis  mean residual lack of closure error divided by the dispersive difference.
R factor  |Fobs  Fcalc||Fobs|, where Fobs and Fcalc are the observed and calculated structure factors, respectively.
Rfree  R factor calculated using 5% (SeMet) or 10% (native and tungstate) of the reflection data chosen randomly and omitted from the start
of refinement.
Rms deviations for bonds and angles are the respective root-mean-square deviations from ideal values.
crystals with P2(1)2(1)2(1) symmetry that diffracted to ment-swapped FHA structures, we will refer to the sev-
enth strand of Chfr as strand 7/8.2.1 A˚ resolution and had two molecules in the asymmet-
ric unit. The structure of this polypeptide was solved by
molecular replacement (Table 1). Both structures were Structure of Conserved Regions
FHA domains have four conserved regions that are re-virtually identical and, unless otherwise specified, the
higher resolution structure will be described. ferred to as boxes A, B, C, and D (Figure 2A) [2]. Box A
consists of a hydrophobic residue followed by a glycine,The FHA domain of human Chfr crystallized as a dimer
(Figure 1A). Each subunit consists of ten  strands and an arginine, and a polar residue. The center two residues
(Gly41 and Arg42 in Chfr) are conserved in all FHA do-a very short  helix between the two C-terminal strands.
The dimer formed by segment swapping (a.k.a. domain mains and map to the C terminus of strand 3 and the
loop that connects strands 3 and 4, respectively (Figureswapping) [9, 10], whereby each folded domain consists
of two segments, each derived from a different molecule. 2B). Box B contains serine and histidine residues (Ser57
and His60 in Chfr) that are conserved in all FHA domains.The first segment contributes the N-terminal six strands
and the N-terminal half of the seventh strand of the Ser57 is at the loop that connects strands 4 and 5, and
His60 is at the N terminus of strand 5. The hydroxyldomain; the second segment contributes the C-terminal
half of the seventh strand, the C-terminal three strands, oxygen of Ser57 is within 4.0 A˚ of the N	 of His60, as
the peptide backbone in this region adopts a kinkedand the  helix. The overall fold of the domain is similar to
that previously reported for the Rad53 N-FHA and C-FHA conformation that allows the side chains of these two
residues to be close to each other. Box C representsdomains. The seventh strand of Chfr corresponds to
Rad53 strands 7 and 8 and the loop connecting these the longest stretch of conserved residues in FHA do-
mains and consists of highly conserved aspartic acid,two strands (Figure 1B). Thus, to have a consistent num-
bering scheme when comparing monomeric and seg- serine, glycine, threonine, and asparagine residues
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Figure 1. Structure of the Chfr FHA Domain
(A) Structure of the segment-swapped dimer.
The two polypeptide chains are colored red
and green, respectively. N, N terminus; C, C
terminus.
(B) Comparison of the structures of the Chfr
FHA and Rad53 N-terminal FHA domains.
Only one domain of Chfr is shown, and the 
strands involved in segment swapping are
not shown in their entirety. In both structures,
strands 1–7 and 8–11 are colored green and
red, respectively, to maintain the same color-
ing scheme as in (A).
(Asp76, Ser78, Gly81, Thr82, and Asn85 in Chfr). Asp76 protein oligomers [12–14]. Finally, box D contains a gly-
cine followed by an aspartic acid (Gly100 and Asp101at the C-terminal end of strand 6, Ser78 at the loop
connecting strands 6 and 7, and Thr82 at the N terminus in Chfr). In Chfr, Asp101 is at the N terminus of strand
10 and forms a salt bridge with Lys86 from the otherof strand 7, together with box B conserved residues
Ser57 and His60, form a cluster of polar/charged resi- subunit (Figure 2B).
dues that interact with each other through hydrogen
bonds. Specifically, the side chain of Asp76, which is Structure of the Chfr-Tungstate Complex
To explore the ability of the Chfr FHA domain to recog-completely buried, forms hydrogen bonds with Ser78
and Thr82, whose side chains are also buried. Thr82 nize phosphate, we formed crystals of the polypeptide
containing residues 14–128 of Chfr in the presence ofalso forms a hydrogen bond with His60. In addition, the
hydroxyl oxygens of Ser78 and Ser57 and the N
 of tungstate. Tungstate has similar molecular geometry
and charge as phosphate and has been used extensivelyHis60 are within 3.6–4.3 A˚ of each other. The C terminus
of box C corresponds to the middle of strand 7/8, where as a phosphate analog in crystallization studies [15–17].
The Chfr-tungstate complex formed crystals withthe polypeptide chain traverses from one folded domain
to another. This region adopts a structure referred to as P3(2)21 symmetry that diffracted to 2.0 A˚ resolution. The
structure factor amplitudes derived from such a crystala polar zipper, an antiparallel  sheet, which, in addition
to the main chain hydrogen bonds, is stabilized by hy- and the previously refined model (without tungstate) in
the P3(2)21 space group were used to calculate a model-drogen bonds formed by asparagine or glutamine side
chains [11]. In Chfr, the side chain hydrogen bonds are phased Fo  Fc difference map. This map showed a
single peak with intensity greater than 4.0 , indicatingformed by the highly conserved Asn85, which interacts
with Asn85 from the other subunit (Figure 2B). A very the presence of a tungstate ion in the crystal. The struc-
ture of the Chfr-tungstate complex was refined andsimilar structure is adopted by the linker region of seg-
ment-swapped dimers of RNase A and possibly by other showed interactions of the tungstate with conserved
Structure
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Figure 2. Structure of Conserved Regions
(A) Amino acid sequence and secondary structure of the crystallized Chfr FHA domain (residues 14–124) aligned to conserved sequences
(boxes A–D) of FHA domains from other proteins. The amino acid sequence numbering refers to the full-length proteins and indicates the
position of the conserved boxes or, for Chfr, marks the entire sequence and selected residues. Rad53-N and Rad53-C, N- and C-terminal
FHA domains of budding yeast Rad53; Dun1, FHA domain of budding yeast Dun1 checkpoint kinase; NBS1, FHA domain of human DNA
repair and cell cycle checkpoint protein NBS1; MNF, FHA domain of mouse MNF transcription factor; Fkh1, FHA domain of budding yeast
Fkh1 transcription factor.
(B–C) Comparison of the structures of Chfr FHA and Rad53 N-FHA domains showing the side chains of amino acids conserved in FHA
domains. The Rad53 N-FHA domain is bound to a phosphothreonine (pT)-containing peptide. Backbone of the FHA domains corresponding
to boxes A–D, orange; phosphopeptide, light blue; phosphate group, red. D3, aspartic acid three residues C-terminal to the phosphothreonine.
residues mostly in boxes A and B (Figure 3B). Specifi- Boxes A and B are involved in phosphate/tungstate
binding in all three FHA domains, but there are differ-cally, the backbone nitrogen of Gly58 (box B) and the
hydroxyl oxygen of Thr79 (box C) are within 2.6–2.9 A˚ ences in the way the ligand is recognized; the Chfr and
Rad53 N-terminal FHA domains turn out to be closelyof a tungstate oxygen atom; in addition, the hydroxyl
oxygen of Ser57 (box B) and the N of Arg42 and Arg43 related, whereas the Rad53 C-terminal FHA domain is
more divergent (Figure 3). The Chfr-tungstate contacts(box A) are within 3.0–3.2 A˚ of a tungstate oxygen atom
(Figures 3B and 3F). Comparison of the native Chfr do- that are conserved in the Rad53 N-terminal FHA-phos-
phopeptide structure involve the side chains of Arg42main to the Chfr-tungstate complex reveals that tung-
state binding has very minor effects on the conformation of box A (Arg70 in Rad53), Ser57 of box B (Ser85 in
Rad53), and Thr79 of box C (Thr106 in Rad53) and theof Chfr limited to the side chains of Arg42, Arg43, and
Thr79 (Figures 3A and 3B). backbone nitrogen of Gly58 of box B (Asn86 in Rad53).
Chfr makes an additional contact with tungstate through
the side chain of Arg43 of box A (Asn71 in Rad53),Comparison to Rad53 FHA Domains
To identify structural features that are conserved in FHA whereas the Rad53 N-FHA domain makes an additional
contact to phosphate through the side chain of Asn86domains, we compared the structures of the Chfr FHA
domain to the structures of the Rad53 N-terminal and of box B (Gly58 in Chfr). The C-terminal Rad53 FHA
domain contacts phosphate through the side chains ofC-terminal FHA domains, which have been determined
in complex with phosphopeptide ligands [4–7]. We fo- Arg605 of box A (Arg42 in Chfr) and Arg617 and Arg620
of box B (Leu55 and Gly58 in Chfr). Of these three inter-cused our comparison on boxes A, B, C, and D, which
show the highest sequence similarity. actions, only the first is conserved in Chfr. The third
Chfr FHA Domain Structure
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Figure 3. Structure of the Chfr-Tungstate
Complex and Comparison to Rad53 FHA Do-
main-Phosphopeptide Structures
(A–D) Comparison of the structures of native
Chfr, the Chfr-tungstate complex, and the
Rad53 N-FHA and C-FHA domains bound to
phosphothreonine (pT)- and phosphotyro-
sine (pY)-containing peptides, respectively.
Backbone of the FHA domains correspond-
ing to boxes A–D, orange; phosphopeptides,
light blue; phosphate and tungstate (WO4)
groups, red. D3, aspartic acid three resi-
dues C-terminal to the phosphothreonine.
(E) Superimposition of the structures of the
Chfr-tungstate and Rad53 N-FHA and C-FHA
domain-phosphopeptide complexes. FHA
domain backbones, gray (various shades);
side chains that contact tungstate/phos-
phate, red (Chfr), green (Rad53 N-FHA), and
blue (Rad53 C-FHA); tungstate ion that binds
to Chfr, red; phosphothreonine (pT) residue
that contacts the Rad53 N-FHA domain, yel-
low and green; phosphotyrosine (pY) residue
that contacts the Rad53 C-FHA domain, yel-
low and blue.
(F) Alignment of Chfr FHA and Rad53 N-FHA
and C-FHA domain residues involved in tung-
state/phosphate binding. Residues whose
side chains are within 3.2 A˚ of a tungstate/
phosphate oxygen atom, red; residues whose
backbone nitrogen (N) contacts a tungstate/
phosphate oxygen atom, blue.
interaction involving Arg620 of box B, although not con- domains. Based on the sequences corresponding to
boxes C and D [1, 2], we propose that FHA domainsserved in Chfr, shares some similarity to the interaction
mediated by Arg43 of box A of Chfr (Figures 3B, 3D, can be divided into families. One family includes FHA
domains present in cell cycle checkpoint proteins, suchand 3E). Consistent with the high number of conserved
protein-ligand interactions between the Chfr and Rad53 as Chfr and Rad53. Another family includes FHA do-
mains present in transcription factors with forkhead-N-terminal FHA domains, the tungstate and phosphate
ligands of the domains superimposed quite well (within type DNA binding domains, such as MNF and Fkh1. The
first family is characterized by the presence of charged0.7 A˚ of each other), whereas the phosphate ligand of
the Rad53 C-terminal FHA domain was about 5 A˚ away and polar residues in boxes C and D, which correspond
to residues Asp76, Ser78, Thr82, and Asp101 of Chfr.(Figure 3E).
Despite the similarities in tungstate/phosphate recog- In the second family, the corresponding residues are
mostly hydrophobic (Figure 2A). Because of their closenition between the N-terminal Rad53 and Chfr FHA do-
mains, the two domains are likely to recognize different proximity to ligand binding residues, the buried box C
residues at the interface of strands 6 and 7 may modu-peptide sequences. The Rad53 N-FHA domain has a
preference for aspartic acid three amino acids C-ter- late the binding properties of the FHA domain. The
C-terminal residue of box C is a highly conserved aspar-minal to the phosphothreonine [4, 7], a preference medi-
ated by an electrostatic interaction between the aspartic agine (Asn85 in Chfr, Asn112 in Rad53) at the end of
strand 7 (Figure 2). Asparagine is frequently present atacid of the peptide and Arg83 of box B (Figure 3C). The
corresponding residue in Chfr, Leu55, would be unable ends of  turns [18, 19], and its conservation in virtually
all FHA domains may help define the end of strand 7.to make a similar interaction.
Box C represents the longest stretch of conserved Box D corresponds to strand 10 and is quite short in
length. The aspartic acid residue in this box (Asp101 inresidues in FHA domains, yet these residues, with the
exception of Thr79 (Thr106 in Rad53), do not directly Chfr, Asp128 in Rad53) is conserved only in the cell
cycle family of FHA domains. In Chfr it participates incontact tungstate/phosphate. Most of the conserved
box C residues form a cluster of amino acids with buried intersubunit interactions with Lys86, but, in the N-FHA
domain of Rad53, it forms a hydrogen bond with Asn112,charged and polar side chains (Asp76, Ser78, and Thr82
in Chfr) at the interface of strands 6 and 7 and in close the conserved box C asparagine at the end of strand 7.
proximity to conserved box B residues (Ser57 and His60
in Chfr). The entire cluster is remarkably similar in the Segment Swapping
The observation that the FHA domain of Chfr crystallizedChfr and Rad53 N-FHA domains (Figures 2B and 2C),
even though these buried residues cannot directly bind as a segment-swapped dimer was unanticipated from
the structures of the N-FHA and C-FHA domains ofligand. The high degree of similarity prompted us to
compare the amino acid sequences of multiple FHA Rad53. We therefore sought to obtain additional crystal-
Structure
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lographic and noncrystallographic evidence for seg- protein that had not been set up for crystallization and
the protein that had formed amorphous precipitatement swapping in Chfr FHA domain crystals. First, we
explored whether it was possible to refine the structure showed identical elution profiles, corresponding to
monomers. In contrast, the protein derived from theusing a chain trace that conferred the same topology
as monomeric Rad53 instead of the chain trace that crystals eluted more slowly, corresponding to the size
of a dimer (Figure 4D). This result is consistent with theconnected two adjacent FHA domains to make a seg-
ment-swapped dimer. The differences in the two traces Chfr FHA domain in the crystals existing as segment-
swapped dimers that did not dissociate to monomersinvolved very few residues (Asn85, Lys86, and Leu87).
However, refinement of the trace with the Rad53 topol- during the 30 min time frame of the gel filtration chroma-
tography run. Dissociation of segment-swappped di-ogy led to several problems, including steric hindrance
involving the C, C, H, and H atoms of Lys86 across mers requires at least partial unfolding of the domain
and would be predicted to be slow, based on the kineticscrystallographic symmetry-related monomers (Figure
4A), disallowed phi/psi angles for residues Asn85 and of protein unfolding [20]. Indeed, the conversion of the
cell cycle yeast protein suc1 from its monomeric to seg-Lys86, negative FoFc density for the bond we arbitrarily
introduced between Asn85 and Lys86 to create the ment-swapped dimeric form is very slow, due to a kinetic
barrier imposed by the denatured state intermediate [21].monomer model, and higher R and Rfree values. As a
second way to validate the segment-swapped model,
we calculated simulated annealing omit maps for both
Biological ImplicationsP3(2)21 and P2(1)2(1)2(1) space groups using models in
which all atoms within 3 A˚ of Lys86 were omitted. These
The ability of the Chfr FHA domain to bind tungstatemaps clearly showed density consistent with a segment-
suggests that, in vivo, Chfr interacts through its FHAswapped dimer (Figure 4B).
domain with phosphorylated proteins. The identity ofTo obtain noncrystallographic evidence for segment
these proteins remains elusive. However, since Chfr is aswapping, we studied the oligomerization state of the
mitotic checkpoint protein, its ligands might be proteinsChfr FHA domain using biophysical approaches. The
phosphorylated by kinases, such as Bub1, BubR1, andfirst step in this analysis was to determine whether, after
Mps1, that are activated in response to mitotic stresspurification, the Chfr FHA domain was a monomer or
[22–24]. At the atomic level, it is interesting that thedimer. Freshly purified polypeptide containing residues
Chfr and the N-terminal Rad53 FHA domains recognize14–128 was examined by analytical ultracentrifugation
tungstate/phosphate mostly through the same con-and was shown to be a monomer that could, however,
served residues, whereas the structure of the C-terminalform dimers with a dissociation constant of 0.15 mM for
Rad53 FHA domain bound to a phosphotyrosine-con-the monomer-dimer equilibrium (Figure 4C). Unfortu-
taining peptide shows that this domain recognizes phos-nately, the analytical ultracentrifugation analysis does
phate through residues that are mostly not conservednot identify whether the dimers are formed by segment
in the former two FHA domains. The distinct architectureswapping or by simple juxtaposition of two indepen-
may reflect intrinsic differences in the mechanism bydently folded domains. Nevertheless, these results indi-
which distinct FHA domains recognize phosphate orcate that, during purification, when the protein concen-
may be due to the different nature of the ligands used.tration would be below 0.15 mM, the Chfr FHA domain
In relation to the former, a cluster of buried polar andwould be mostly a monomer, whereas, after concentra-
charged residues, adjacent to the residues that directlytion, in preparation for crystallization, the domain would
contact ligand, is conserved in FHA domains present inbe mostly a dimer.
cell cycle checkpoint proteins but not in FHA domainsAnalytical ultracentrifugation was not an option for anal-
present in transcription factors. Based on this differ-ysis of Chfr FHA domain protein extracted from crystals
ence, we propose that FHA domains can be divided intobecause of its low sensitivity; we therefore resorted to
families that will likely have distinct binding properties.gel filtration analysis using a protein purification system
A surprising feature of the Chfr FHA domain structuredesigned for protein quantities in the micromolar range.
was the presence of segment swapping involving anAbout 20 Chfr FHA domain crystals were washed exten-
exchange of four C-terminal  strands and an  helixsively in stabilization buffer and dissolved by dilution in
between molecules. This phenomenon was first ob-buffer that contained no PEG precipitant. After spinning
served in crystals of the diphtheria toxin, and the termto remove particulate material, the solubilized protein
domain swapping was introduced to describe it becausewas run on the gel filtration column. As a control, we
an entire structural domain of the multidomain diphthe-examined the entire contents of a drop that had been
ria toxin protein is exchanged [25]. However, in Chfr,set up for crystallization and which had a considerable
as in most examples described since the term domainamount of amorphous protein precipitate but no crys-
swapping was introduced, only part of a protein domaintals. The amorphous precipitate in the drop was dis-
is exchanged [9, 10]. We therefore adopted the termsolved by dilution in buffer without PEG, and, therefore,
segment swapping to describe examples, such as thatthis sample was very similar to the sample of solubilized
of Chfr, in which multiple secondary structure elements,FHA crystals in buffer and protein composition. A further
but not entire structural domains, are exchanged be-control included purified protein that had not been set up
tween subunits.for crystallization. During the gel filtration run, the protein
There are several examples of segment-swappedconcentration in all three samples was at least ten times
structures, but they represent a very small fraction of allbelow the value of the monomer-dimer dissociation con-
stant calculated by analytical ultracentrifugation. The determined protein structures [9, 10]. The physiological
Chfr FHA Domain Structure
897
Figure 4. Segment Swapping
(A) Refined monomer and segment-swapped dimer models in the P3(2)21 space group. The hydrogens of the Lys86 side chain are shown to
indicate the presence of steric hindrance in the monomer model. The two polypeptide chains are colored green and red, respectively.
(B) Simulated annealing omit electron density maps contoured at 1.5 . The maps were generated using the refined monomer model in the
P3(2)21 space group (left) or the refined segment-swapped dimer model in the P2(1)2(1)2(1) space group (right), with all atoms within 3 A˚ of
Lys86 omitted. For both maps, the refined segment-swapped dimer models are shown to indicate that these models fit the omit electron
density maps.
(C) Analytical ultracentrifugation analysis of the polypeptide containing residues 14–128 of Chfr. Lower panel: protein concentrations at
equilibrium for the three initial loading concentrations (1.0, 0.5, and 0.25 mg/ml) at 33,800 rpm and 4C. Circles, raw data; lines, fitted curves
for monomer-dimer equilibrium. Upper panels: residuals of the fitted curves to the data points for each concentration from highest to lowest
(top to bottom, respectively).
(D) Gel filtration chromatography elution profiles of Chfr FHA domain immediately after purification (Stock) or after extraction from amorphous
precipitate (Precip.) or crystals (Crystal). The Stock, Precip., and Crystal elution profiles correspond to molecular sizes of 11.6, 11.5, and 20.6
kDa, respectively.
significance of segment swapping is unclear, although synthase and the ligand binding properties of suc1 [28–
30]. It is too premature to state whether segment swap-evidence is accumulating that it is relevant in vivo. For
example, amyloid formation in patients with amyloid an- ping in the Chfr crystal structure is relevant in vivo. As
yet, there is no evidence that Chfr or other FHA domain-giopathy and transmissible encephalopathies may be
mediated by segment swapping and subsequent oligo- containing proteins form dimers in vivo. Nevertheless,
certain features important for the stabilization of themerization of cystatin C and the cellular prion protein
PrP(C), respectively [26, 27]. In addition, segment swap- segment-swapped dimer, such as the asparagine at the
end of strand 7 (Asn85 in Chfr) and the length of the loopping may be required for Flp recombinase to be active
and may regulate the enzymatic activity of nitric-oxide between strands 7 and 8, are conserved in most FHA
Structure
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complex structure was determined by refining the P3(2)21 spacedomains, raising the possibilty of functional signifi-
group structure against the structure factor amplitudes obtainedcance.
from the Chfr-tungstate complex crystal and calculating a model-In conclusion, the Chfr FHA domain structure reveals
phased Fo  Fc difference map, which showed the position of thethe capacity for phosphate binding, a structurally con- tungstate ion. The Chfr-tungstate complex structure was refined
served cluster of buried polar and charged residues next using the programs O and CNS; after multiple cycles of refinement,
the occupancy of the tungstate ion was calculated to be 0.47.to the phosphate binding site, and segment swapping.
Figures were prepared using the programs MOLSCRIPT [35],Amino acid substitution mutants, whose design is based
RASTER3D [36], and BOBSCRIPT [37].on the three-dimensional structure, can now be used
to probe the functional significance of these structural
Analytical Ultracentrifugation
features and better understand a protein that is mutated The oligomerization state of the Chfr FHA domain was analyzed
in human cancer. using sedimentation equilibrium in a Beckman XL-1 analytical ultra-
centrifuge. The polypeptide containing residues 14–128 of Chfr was
Experimental Procedures tested at protein concentrations of 0.25, 0.5, and 1.0 mg/ml in buffer
containing 20 mM bis-Tris (pH 6.5), 150 mM KCl, and 5 mM DTT at
Protein Expression and Purification centrifugation speeds of 33,800 and 48,900 rpm at a temperature
The human Chfr FHA domain (residues 14–124 or 14–128) was ex- of 4C. Attainment of equilibrium was determined by comparing
pressed in E. coli BL21 cells at 30C. Cells were lysed in buffer successive scans acquired using interference optics. The scans
consisting of 25 mM bis-Tris propane (BTP) (pH 6.8), 240 mM NaCl, acquired at 28 hr were used to calculate the monomer-dimer associ-
5 mM DTT, and protease inhibitors, and the FHA domain was purified ation constants as previously described [38].
by cation exchange (Resource S column; Pharmacia) and gel filtra-
tion (Superdex 200 column; Pharmacia) chromatography. The pro- Gel Filtration Analysis for Domain Swapping
tein eluted from the gel filtration column in buffer consisting of 20 Fifty microliters of stabilization buffer without PEG (100 mM bis-Tris
mM bis-Tris (pH 6.5), 150 mM KCl, and 5 mM DTT. [pH 6.5], 150 mM KCl, and 5 mM DTT) were added either to Chfr
FHA protein that had not been set up for crystallization, to one
drop of protein that had been set up for crystallization and whichCrystallization and Data Collection
contained amorphous precipitate but no crystals, or to about 20Crystals were grown at 4C by the hanging drop vapor diffusion
harvested crystals that had been extensively washed in stabilizationmethod by mixing the protein with an equal volume of reservoir
buffer. The samples were spun to remove any particulate materialsolution containing 14%–18% polyethylene glycol (PEG) 8000, 100
and run on a micropurification gel filtration column (Sephadex 200mM bis-Tris (pH 6.5), and 5 mM DTT. Crystallization started at 2–3
PC; column volume, 2.4 ml) on a SMART protein purification systemdays, and crystals grew to their final size over a 2–4 week period.
(Pharmacia) at a flow rate of 80 l/min. Each chromatography runCrystals of the native polypeptide containing residues 14–124
lasted about 30 min. To assign subunit stoichiometry, we comparedformed in space group P2(1)2(1)2(1), with a  54.90 A˚, b  52.90 A˚,
the elution profiles of the samples to the elution profiles of molecularand c  77.25 A˚, and contained two molecules in the asymmetric
size standards.unit. Crystals of selenomethionine (SeMet)-labeled polypeptide con-
taining residues 14–128 formed in space group P3(2)21, with a 
b  62.36 A˚ and c  54.25 A˚, and contained one molecule in the Acknowledgments
asymmetric unit. Some of the SeMet-labeled crystals were soaked
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